Payment overview · 2025
General Payments
$733.47
39 reported records · 17 companies
Healthcare provider profile · identity verified
Mark R Freije, MD
Allopathic & Osteopathic Physicians|Family Medicine · CARMEL, IN · NPI 1932317849
Verified facts
What the public records show
CMS Open Payments records show Mark R Freije, MD received $733.47 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.25 | 18.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $127.18 | 17.3% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $64.35 | 8.8% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $63.77 | 8.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.60 | 7.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.77 | 5.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.36 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.93 | 4.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.97 | 4.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.59 | 3.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.82 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.63 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.62 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.55 | 2.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.81 | 2.0% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $13.17 | 1.8% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $11.10 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $733.47 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.49 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.96 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $67.29 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $64.35 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $63.77 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.60 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.76 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $13.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 116 |
| Lisinopril | Lisinopril | 288 | 82 |
| Losartan Potassium | Losartan Potassium | 272 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 71 |
| Simvastatin | Simvastatin | 217 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 55 |
| Omeprazole | Omeprazole | 204 | 63 |
| Metformin Hcl | Metformin Hcl | 192 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 55 |
| Allopurinol | Allopurinol | 167 | 49 |
| Gabapentin | Gabapentin | 151 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 43 |
| Montelukast Sodium | Montelukast Sodium | 139 | 43 |
| Alprazolam | Alprazolam | 125 | 33 |
| Metformin Hcl Er | Metformin Hcl | 120 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 31 |
| Trazodone Hcl | Trazodone Hcl | 107 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 32 |
| Sertraline Hcl | Sertraline Hcl | 103 | 29 |
| Eliquis | Apixaban | 99 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 34 |
| Furosemide | Furosemide | 96 | 33 |
| Tramadol Hcl | Tramadol Hcl | 95 | 20 |
| Meloxicam | Meloxicam | 93 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 20 |
| Carvedilol | Carvedilol | 80 | 24 |
| Clonazepam | Clonazepam | 79 | 17 |
| Lorazepam | Lorazepam | 72 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 22 |
| Glimepiride | Glimepiride | 69 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 19 |
| Potassium Chloride | Potassium Chloride | 64 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 17 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Ezetimibe | Ezetimibe | 60 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 20 |
| Famotidine | Famotidine | 54 | 18 |
| Jardiance | Empagliflozin | 54 | 13 |
| Bupropion Xl | Bupropion Hcl | 53 | 18 |
| Alendronate Sodium | Alendronate Sodium | 51 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 11 |
| Spironolactone | Spironolactone | 49 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 24 |
| Methylprednisolone | Methylprednisolone | 45 | 39 |
| Ozempic | Semaglutide | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Atenolol | Atenolol | 39 | 13 |
| Sulindac | Sulindac | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Finasteride | Finasteride | 36 | 11 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 19 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Cephalexin | Cephalexin | 25 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Glipizide | Glipizide | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 18 |
| Estradiol | Estradiol | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nalbuphine Hcl | Nalbuphine Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Edluar | Zolpidem Tartrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $733.47 · 39 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Azstarys, BREZTRI, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, Kerendia, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error